Navigation Links
FTC Ends Investigation of CVS Caremark
Date:1/12/2012

nd services that differentiate us and benefit consumers," said Larry Merlo, President and Chief Executive Officer of CVS Caremark.  "We remain committed to delivering the best possible pharmacy care by driving down health care costs, expanding consumer access and improving health care outcomes.    

"During the course of this two year investigation, our company cooperated fully with the FTC and provided to the government millions of documents as well as access to numerous members of our management team who participated in voluntary interviews and depositions," said Douglas A. Sgarro, Executive Vice President and Chief Legal Officer of CVS Caremark.  "It is important to note that, at the conclusion of this comprehensive investigation, the FTC made no allegations of antitrust law violations or anti-competitive behavior associated with any of our business practices, products or service offerings."

About CVS Caremark
CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,300 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information ab
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... company developing its Symphony® CGM System as a ... that Robert F. Doman , Executive Chairman ... at "TEN", Noble Financial Capital Markets, Tenth Annual ... make a corporate presentation to prospective corporate partners ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced that it expects revenues for ... $53 million, bringing expected full-year 2013 revenues to ... growth of 87% for 2013 above 2012 reflects ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
(Date:4/14/2014)... April 14, 2014 Popular web information on ... to read and doesn,t address the appropriate risks to ... Medical Center gastroenterologists suggests. , In a review of ... education materials for colorectal cancer screening were written beyond ... sites failed to address key risks, as well as ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
(Date:4/14/2014)... Frank Porter Graham Child Development Institute have released ... program to prepare four-year-olds for success in kindergarten. ... Pre-K show significant gains across all areas of ... even greater rate during their participation in NC ... senior scientist Ellen Peisner-Feinberg, who leads the FPG ...
(Date:4/14/2014)... Ohio Heart patients with beliefs about health that ... skip sessions of cardiac rehabilitation, new research suggests. , ... of these beliefs referred to as "irrational health ... was associated with lower adherence to a prescribed cardiac ... Doubting the preventive power of the flu vaccine or ...
(Date:4/14/2014)... high-risk bladder cancer, chemotherapy before or after surgery ... The findings are published early online in ... Cancer Society. , Clinical trials have shown that ... cancer who are given chemotherapy before surgery. There ... also improves survival. To investigate the use of ...
Breaking Medicine News(10 mins):Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... , FERNDALE, Mich. and NEW YORK, Aug. ... today the acquisition of PRESCRIBED solutions [CUSTOMIZED SKINCARE]. Since ... among top dermatologists and plastic surgeons with its innovative, customizable ... product Stop the Clock(TM) Triple Action Anti-aging Day ...
... , SAN FRANCISCO, Aug. 14 While natural ... higher than 50 percent and none have been clinically proven to regulate ... e alth International (NHI), a vertically integrated San ... line has been clinically proven to alleviate symptoms of menopause in ...
... minimize the risk as fall looms, experts say , FRIDAY, ... year have another worry besides homework and lunchroom bullies: swine ... early and vigorously to reduce their risk of contracting the ... is going to strike the school-age child and it,s primarily ...
... , , BELLEVUE, Wash., Aug. ... solutions, today announced the new Edifecs5010(TM) Compliance ... and services for healthcare providers, payers, health plans, ISVs, and clearinghouses ... , , Edifecs, the gold standard for HIPAA ...
... , , KENILWORTH, N.J., Aug. ... announced that the U.S. Food and Drug Administration (FDA) has ... in adults and acute treatment of manic or mixed episodes ... in adults. SAPHRIS can be used as a first-line treatment ...
... , NEW YORK, Aug. 14 MS -- ... by AstraZeneca, found that while most patients with asthma understand ... accordingly. , , "This finding demonstrates ... and the necessary steps people should take to achieve better ...
Cached Medicine News:Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 2Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 3Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2Health News:Get Smart About Swine Flu for Back-to-School 2Health News:Get Smart About Swine Flu for Back-to-School 3Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Keeping Asthma Under Control 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: